Wednesday, May 6, 2020
Southwestââ¬â¢s Competititve Advantage Free Essays
STRATEGY IMPLEMENTATION AND MEASUREMENT METRICS ASSIGNMENT-1 SOUTHWEST AIRLINES CASE STUDY QUESTIONS 1. How does Southwest Airlines get its competitive advantage? 2. How does Southwest Airlines execute its strategy? 1. We will write a custom essay sample on Southwestââ¬â¢s Competititve Advantage or any similar topic only for you Order Now How does Southwest Airlines get its competitive advantage? Southwest Airlines uses a Cost Leadership Strategy, however most pricing strategists would agree that having a low price does not, in itself, constitute a competitive advantage. In fact, thinking that low prices are always a good strategy for competition is deeply misguided. However, at times, targeting low prices can lead to a strategic focus which delivers tremendous results. Modern competitive strategy will often examine firms from a resource-based view. According to this lens, competitive advantage derives from leveraging an inimitable resource to deliver value at a lower cost than the competitors. Price is a completely imitable resource. Any company can match the prices of its competitor if it so chooses. Hence, arguing that a low price is a strategic resource, or that it leads to a competitive advantage in and of itself, is illogical. Southwest Airlines has used the target pricing and utilized a marketing orientation since its infancy in 1971, even though these concepts were not fully defined back then. First, starting with the customers and the value they sought, Southwest Airlines initial target was customers traveling between cities in Texas, specifically between Dallas and Houston, Dallas and San Antonio, San Antonio and Houston. While Texas is larger than many countries, it isnââ¬â¢t so large that people canââ¬â¢t drive from city to city. Hence initially, the most comparable alternative to Southwest, and therefore its prime competition, wasnââ¬â¢t other airlines. Instead, it was the car. In uncovering the car as the competing alternative, Southwest was able to also identify the target price of its offering. Second, to compete with the car, Southwest Airlines had to price their service relatively similar to the cost of car travel. With this target in mind, they chose $20. While $20 is lower than the government allowable tax deduction for travel, it is also significantly higher than the price of gas alone to drive between these cities. Thus, at this $20 price, Southwest Airlines could be confident that it would capture many of the travelers that would have driven and convert them into short-hop air travelers. Third, the product was redefined to serve customers at this low price profitably. Consider what was removed from air travel and what was included instead. The table below enumerates the key points Points 1 Removed Reduced reservations flexibility: Reservations primarily made directly Southwest Airlines as they eschewed working with travel agents. No connections between airlines: Southwest Airlines would not transfer baggage between flights. Included or Added Simplicity in Pricing: Flat rate of $20 per leg of the journey. Also reduced the cost of price management, as no yield management system was needed initially. Higher convenience in terms of on-time arrivals: With a simplified fight route between lesser used airports, Southwest was able to operate more reliably. Higher convenience in flight frequency: With point to point flights, Southwest could offer service between Houston and Dallas with the same plane roughly every 2. hours. 2 3 No long-haul flights: Southwest Airlines customers could only take Southwest between a city-pair, not across the country or even across state lines initially. This greatly reduced cost of compliance with CAB rulings, as Southwestââ¬â¢s operations were not subject to interstate commerce rulings. 4 No in-flight meals: Southwest Airlines only offered peanuts and beverages. Fun: Friendly flight attendants provided jokes, costumes, and made flying comfortable with warm and caring service. Faster boarding times leading to faster flight turnarounds. More seats: With one class of service, Southwest Airlines could put 137 seats in a 737 versus 128 in a United Airlines 737. 5 6 No seat assignments: First come, first seated. No first class: One-class service. 7 Does not fly into major airports: or uses Use of underutilized airports that are less major airports concentrates on point close to metropolitan cities: reduced to point connections costs, punctuality Use of multiple aircraft types Frequent flyer program does not use miles earned Uses fuel efficient 737s: reduces maintenance and training costs Based on number of trips flown: reduced operating costs 9 From this list, we see a number of items which an airline would usually use to define superior value removed from Southwest Airlines offer. A Southwest customer couldnââ¬â¢t be treated to first class, couldnââ¬â¢t get food, couldnââ¬â¢t book them as part of a larger trip, couldnââ¬â¢t book with them through an agent, and couldnââ¬â¢t even preselect their seat. All of these features were exactly what defined a competitive airline at the time. And, all of these features added cost. Instead, Southwest Airlines selected a specific target customer ââ¬â a Texan traveling between cities in Texas ââ¬â and then determined what it would take to satisfy that customer. ? ? ? That customer was far more interested in travel efficiency than travel class. That customer would be glad to forgo a meal, especially in exchange for a friendly flight attendant and a Dr. Pepper. That customer was trading off driving for flying, and needed flexibility in booking rather than navigating through the decisions and planning related to yield management. This service described does not meet the wants of every customer that could have flown Southwest Airlines, but it does describe those of the target customer. And, given the choice of mediocrely satisfying everyone at a high cost or highly satisfying a select few at a low but profitable price, Southwest Airlines rightly chose the latter. As a result of tightly defining the value sought by customers (efficient and flexible travel), and the price ($20), Southwest was able to meet the needs and surpass the expectations of their target customer. Moreover, it was able to do this at a significantly lower cost than a standard airline. So can low prices deliver a competitive advantage? NO, not alone. But target pricing, where the price and benefits demanded by customer leads to a strategic focus that drives a redefinition of the product and service, can deliver a winning competitive advantage. One where a customer need is met at a cost below the price the target market is willing to pay. BALANCED SCORECARD FOR SWA 2. How does Southwest Airlines execute its strategy? Southwest Airlines is probably one of the most striking examples of a company that (a) Defined a very clear and simple key business purpose, (b) Chose the right business model to support the business purpose, and (c) Consistently demonstrates the core values and behaviors derived from that key business purpose. The brand promise of Southwest Airlines is: ââ¬ËDedication to the highest quality of Customer Service delivered with a sense of warmth, friendliness, individual pride, and Company Spiritââ¬â¢. Every single employee of the company is aligned with this brand promise and in spite of the current economic turmoil in the airline industrySouthwestââ¬â¢s performance isamong the best in the industry. Staff morale is exceptionally high. In 1971, Rollin King and Herb Kelleher started an airline service with one simple notion: ââ¬Å"If you get your passengers to their destinations when they want to get there, on time, at the lowest possible fares, and make darn sure they have a good time doing it, people will fly your airlineâ⬠. Southwest currently has the lowest operating-cost structure in the US domestic airline industry and consistently offers the lowest and most of all simplest fares. Southwest holds the best cumulative customer satisfaction record for the past 18 years. In December 2008, the airline had 35,499 employees and generated total operating revenues of $11 billion (2007 = $ 9. 8 billion, 2001 = $ 5. 3 billion) from a passenger load factor of 71. 2% with a fleet of 537 Boeing 737ââ¬â¢s. Its stock exchange symbol is ââ¬ËLUVââ¬â¢, representing Southwestââ¬â¢s home at Dallas Love Field, as well as the theme of its employee and customer relationships. The major success to their continued success seems due to their low-cost model and competitors being aware that they cannot match Southwest Airlinesââ¬â¢ low prices. Southwest Airlines has the reputation of being able to force a competitor into bankruptcy. It is believed, however, that it was not just the choice of its business model that made Southwest Airlines such a successful company; it is the way they execute their business model through perfect strategic alignment. Southwest Airlines succeeded in defining a very simple yet clear key business purpose; the fact that they aim for being ââ¬Å"the only short haul, low fare, high frequency, point-to-point carrier in Americaâ⬠leaves very little room for interpretation. What makes Southwest Airlinesââ¬â¢ key business purpose such a powerful one however, is not just the very clear definition of their ââ¬Ëraison dââ¬â¢ etreââ¬â¢, but certainly also what the company and its leaders do with it. Their simple but effective key business purpose is the main guiding principle for Southwest Airlinesââ¬â¢ strategic goals, business strategy, organizational infrastructure, and last ââ¬â but certainly not least ââ¬â their company culture. The organization of Southwest Airlines is best described as an upside-down pyramid ââ¬â an organization very much in line with the way they want to do business. The upper management is at the bottom and supports the front line employees, who are the experts. Front line employees play a major role in the yearly business planning and operational budget which for a great part is done bottom-up rather than top-down. This is the fruit of co-founder Herb Kelleherââ¬â¢s unorthodox leadership style, in which management decisions are made by everyone in the organization, not just the head executives. The company does not put much emphasis on structure; instead, employees are encouraged to think freely without constraints such as titles or official mandates. The reason for Southwest Airlineââ¬â¢s success is due to their clear key business purpose and core values, and due to the way in hich they consistently execute their business model (a combination of ââ¬Ëdisruptive innovationââ¬â¢ and ââ¬Ëcustomer intimacyââ¬â¢) in line with their key business purpose and core values. ? ? ? The Southwest Airlines fleet consists solely of Boeing 737s It offers only economy seats (there is no business or first class). Southwest Airlines also do not offer in-flight meals, only peanuts and other snacks. Southwest is simple and direct at the goal of their service; ââ¬Å"A primarily short-haul airline that flies directly from city to city, with just one type of plane ââ¬â the Boeing 737 ââ¬â and the lowest costsâ⬠. With a simple goal, Southwest has excised many of the ââ¬Ëluxuriesââ¬â¢ that competitors offer, such as luxury seats; this is made evident by their decision to enforce a rule for passengers who cannot fit into the seats to purchase an additional seat. This rather unpopular move ââ¬â whereas other airlines would have suggested a more luxury class seat ââ¬â is simple in its purpose ââ¬â get passengers from point A to point B with a minimum of frills, but with a friendly smile and great personal service. While Southwest Airlines offer no frills, they do meet and exceed customer expectations when it comes to personal service. They base their model on the motto ââ¬Å"If employees are happy, satisfied, dedicated, and energetic, theyââ¬â¢ll take real good care of the customers. When the customers are happy, they come back. And that makes the shareholders happyâ⬠. Southwest invests in very good relations with all their employees. Employees are either of independent labor unions or have flexible contracts which allow employees to work longer hours (adapting the business model to the key business purpose) How to cite Southwestââ¬â¢s Competititve Advantage, Essay examples
Wednesday, April 29, 2020
Marine Organisms and Other Novel Natural Sources of New Cancer Drugs Essay Example
Marine Organisms and Other Novel Natural Sources of New Cancer Drugs Essay Gilberto Schwartsmann South-American Office for Anticancer Drug Development (SOAD), Comprehensive Cancer Centre (CINCAN), The Lutheran University (ULBRA) Postgraduate Course in Medicine (UFRGS), Porto Alegre, Brazil Introduction Man has always relied on nature for survival. Since ancient times, nature has been our main source of food, protection, clothing, transportation and remedies [1,2]. This can be illustrated by the number of natural product derived agents currently in use in routine medical practice (Table 1) [3-5]. In addition o plant-derived compounds, microorganisms constitute a very important source of novel bioactive agents. They have contributed to the medical armamentarium with antibiotics such as penicillins, aminoglycosides and cephalosporins, which represent landmarks in the history of human therapeutics [6,7]. Although marine compounds are yet underrepresented in routine clinical practice, it can be anticipated that aquatic environment may become a potentially valua ble source of novel compounds, as the worlds oceans cover about 70% of the earths surface and all except 2 of the 28 major animal phyla are represented there [8-11]. Anti-cancer agents derived from natural sources Several new anticancer agents that entered the market in the 1990s were obtained from natural sources (Table 2) [12,13]. There is also a significant number of naturally derived new anticancer candidate compounds that are currently undergoing preclinical and early clinical development (Table 3) [3,14]. Plant-derived compounds, in particular, have . a special place in the anticancer therapy (Table 4) [15,16]. The Vinca alkaloid vincristine (isolated from Catharanthus roseus) is part of various curative regimens in patients with leukaemia and lymphoma [17,18]. Similarly, the epipodophyllotoxin derivative, etoposide (extracted from the mandrake plant Podophyllum peltatum and the wild chervill P. emodi) is included in drug regimens that produce a significant number of cures in patients with germ-cell tumours [19,20]. The taxoids (extracted from the bark of the Taxaceae Taxus brevifolia, T. canadensis, or T. baccata) and the camptothecins (derived from the bark and wood of the Nyssacea Camptotheca acuminata) have also significant anti-solid tumour Table 1 Drugs developed from plant sources Drug Medical use Plant source Aspirin Atropine Benzoin Caffeine Codeine We will write a custom essay sample on Marine Organisms and Other Novel Natural Sources of New Cancer Drugs specifically for you for only $16.38 $13.9/page Order now We will write a custom essay sample on Marine Organisms and Other Novel Natural Sources of New Cancer Drugs specifically for you FOR ONLY $16.38 $13.9/page Hire Writer We will write a custom essay sample on Marine Organisms and Other Novel Natural Sources of New Cancer Drugs specifically for you FOR ONLY $16.38 $13.9/page Hire Writer Digoxin Eugenol Hygoscyamine Morphine Papaverine Pilocarpine Quinine Reserpine Scopolamine Toxiferine Xanthotoxin Analgpsir, antiinflammatnry Pupil dilator Oral disinfectant Stimulant Analgesic, antitussive For atrial fibrillation and CHF For toothache Anticholinergic Analgesic Antispasmodic For glaucoma For malaria prophylaxis Antihypertensive For motion sickness Relaxant in surgery For vitiligo Filipendula ulmaria Atropa belladonna Sty rax tonkinensis Camellia sinensis Papaver somniferum Digitalis purpura Syzigium aromaticum Hyoscyamus niger Papaver somniferum Papaver somniferum Pilocarpus jaborandi Cinchona pubescens Rauwolfia serpentia Datura stramonium Strychnos guianensis Ammi majus 235 Downloaded from annonc. oxfordjournals. org by guest on December 7, 2010 236 G. Schwartsmann Table 2 Anticancer drugs developed from plant sources Drug Medical use Plant source Etoposide Testicular tumours, small cell lung cancer Teniposide Paediatric acute lymphoblastic leukaemia Vinblastine Hodgkins disease, non-Hodgkins lymphoma, carcinoma of the testis, Kaposis sarcoma, choriocarcinoma, breast cancer Vincristine Acute leukemia, Hodgkins disease, non-Hodgkins lymphoma, rhabdomyosarcoma, Wilms tumour Vindesine Investigational; modest activity in Hodgkins disease, non-Hodgkins lymphoma, leukaemias, non-small cell lung cancer, and breast cancer Vinorelbine Activity in breast and non-small cell lung cancer Paclitaxel Ovarian, breast, lung cancer and others Docetaxel Ovarian, breast, and lung cancers Topotecan Ovarian cancer Irinotecan Colorectal cancer Podophyllum peltatum and P. emodi Podophyllum pellatum and P. emodi Catharanthus roseus Catharanthus roseus Catharanthus roseus Catharanthus roseus Taxus brevifolia Taxus baccata Camptotheca acuminata Camptotheca acuminata Table 3 Examples of natural product derived agents approved for marketing (1990-1999) Bisantrene Interferon y-lA Cytarabine ocphosphate Miltefosine Porfimer sodium Pegaspargase Zinostatin stimalamer Gemcitabine Topotecan Irinotecan Fludarabine phosphate Pentostatin Formes tane Paclitaxel Sobuzoxane Bicalutamide Raltitrexed Docetaxel Lyposomal doxorubicin Lyposomal daunomycin Etoposide phosphate The agents are either natural products, semisynthetic analogues or the pharmacophore is from a natural product. From Cragg and Newman, 1999 [3]. activity [21]. Paclitaxel was approved by the FDA for the treatment of ovarian and breast carcinoma, nd has also important activity against other tumours such as non-small cell lung cancer [22]. Irinotecan and topotecan are more water-soluble semi-synthetic camptothecin derivatives which were approved for the treament of advanced colorectal [23,24], and ovarian carcinoma [25-27], respectively. These agents have also shown clinical antitumour activity in other malignancies of the adult and children [27]. Antitumour antibiotics such as doxorubicin, daunomycin, bleomycin, mitomycin, streptozocin and deoxycoformycin are clinically active agents against several types of cancers [28,29]. They were all isolated rom Streptomyces species. Other microbe-derived metabolites under current development are rhizoxin, deoxyspergualin, UCN-01 (7-hydroxystaurosporin), spicamycin (KRN5500), CC-1065 (bizelesin), and the rebeccamycin analogues [3,30,31]. The epithilone derivatives obtained from myxobacteria have gained Table 4 NCI-sponsored experimental agents whose pharmacophores are obtained from natural sources Source Agent Status Animal Animal Animal Marine Marine Microbial Microbial Microbial Microbial Microbial Microbial Microbial Microbial Microbial Microbial Microbial Microbial Microbial Microbial Plant Plant Plant Pyrimidine base Hydroxydopamine derivative Tributyrin 2-Methoxyestradiol derivative Halichondrin B Dolastatin 10 COL 3 Cordycepin/deoxycoformycin Geldanamycin derivative Iododoxorubicin Rapamycin derivative Vicenistatin Bizelesin Depsipeptide KRN55O0 9-cir-Retinoic acid Quinocarmycin derivative Rebeccamycin derivative Rhizoxin UCN-01 Neriifolin Flavopiridol Perllyl alcohol 5-Ethynyluracyl Preclinical PrecUnical Preclinical Preclinical * Clinical Preclinical Preclinical Preclinical Clinical Preclinical Preclinical Clinical Clinical Clinical Clinical Clinical Clinical Clinical Clinical PrecUnical Clinical Clinical Clinical From Cragg and Newman, 1999 [3]. also attention in the laboratory, because of the similarity of their mechanism of action to the taxoids [32]. Cytosine arabinoside, a synthetic analogue of the C-nuclesides initially isolated from the Caribbean sponge, Cryptotheca cripta, was the first and, so far, only, marine-derived compound routinely used in cancer therapy. It has significant antitumour activity in leukaemias and lymphomas [33,34]. The systematic exploration of marine organisms as sources of novel bioactive agents initiated in the 1970s and Downloaded from annonc. oxfordjournals. rg by guest on December 7, 2010 Marine organisms and other novel natural sources of new cancer drugs 237 expanded markedly since the mid-1980s. Presently, more than 2500 new metabolites were described from a variety of marine sources, anticipating its future role as a valuable source of novel chemical classes not usually found in the terrestrial environment [35-37]. Several potentially i nteresting marine compounds are in preclinical development. Discodermolide, a metabolite of the deep-sea sponge Discodermia dissolute, was collected in the waters of the Bahamas, and it was shown to induce microtubule stabilisation [35]. Halichondrin B, first isolated from the sponge Halichondria okadai in Japan has shown in vivo activity against melanoma and leukaemia. It is being currently obtained from the New Zealand deep-water sponge Lissodendoryx. Isogranulatimide, an aromatic alkaloid extracted from the Brazilian tunicate, ascidian Didemnum granulation, acts as a G2 checkpoint inhibitor. Its synthesis has been fully accomplished and several analogues are being developed [36]. Experimental anticancer agents in phase Iââ¬âII trials Tunicate derivatives Of the marine compounds that have entered clinical evaluation, three ââ¬â didemnin B (DB), aplidine DDB) and ecteinascidin 743 (ET 743) ââ¬â are derived from tunicates. DB is a cyclic depsipeptide isolated from the tunicate Trididemnum solidum and was the first to enter phase I and II studies. In phase II trials sponsored by the NCI, partial and complete tumour responses were documented in patients with non-Hodgkins lymphoma. However, DB caused cardiot oxicity and was stopped in its further development. DB also produced significant nausea and vomiting, and isolated cases of hypersensitivity reactions [36-38]. Aplidine was obtained from a Mediterranean colonial tunicate, Aplidium albicans. It has a pyruvyl group replacing the lactyl group in DB and its synthesis has been achieved. It appears more active than DB in preclinical models and apparently not cardiotoxic. Aplidine entered clinical trials in 1999 both in Europe and in the US under the sponsorship of the Spanish company Pharma Mar. The ecteinascidins (Ets) are derived from the Caribbean tunicate Ecteinascidia turbinata. Following a period of supply problems, enough amounts of this compound could be obtained from aquaculture and synthesis. The derivative Ecteinascidin 743 (ET 743) showed promising activity in murine and human tur, II â⬠¢ o gt; = 0 à «A/V II I I Fig. 1. Chemical structure ET743. mour models, and is currently in early clinical development (Fig. 1) [39,40]. It is a tetrahydroisoquinoline alkaloid that alkylates selectively guanine N2 from the DNA minor groove, and this alkylation is reversed by DNA denaturation. Therefore, it differs from other DNA alkylating agents so far used in the clinic [40]. Dolastatins The dolastatins are cytotoxic peptides, which can be cyclic or linear, derived from the sea hare, Dolabella auricularia, a mollusc from the Indian Ocean. Dolastatin 10 and 15 are small peptides that were shown o interact with tubulin. Dolastatin 10 (NSC 376128) was selected for initial clinical development because of its more favourable preclinical profile (Fig. 2). It is extremely potent in vitro and it was shown to inhibit microtubule assembly, tubulin-dependent guanosine triphosphate (GTP) binding and inhibit vincristine and vinblastine binding to tubulin. It causes cells to accumula te in metaphase arrest and is modulated by the MDR gene product [41,42]. Dolastatin 10 has in vitro activity against several human leukaemia, lymphoma and solid tumour cell lines with IC50S between 0. 1 to 10 nM. It has documented ntitumour activity in various human solid tumour models, such as LOX#IMVI melanoma, OVCAR- 3 ovarian carcinoma and NCI-H522 NSCLC O CH3 OCH3O H3CO Fig. 2. Structure of dolastatin 10 (NSC 376128). Downloaded from annonc. oxfordjournals. org by guest on December 7, 2010 238 G. Schwartsmann Fig. 3. Structure of bryostatin-1 (NSC 339555). cell lines. In animal toxicology studies, myelosuppression was the dose-limiting toxicity. This agent is highly bound to plasma proteins and pharmacokinetic studies in animals showed a rapid degradation probably by hepatic metabolism [43,44]. This agent entered phase I trials as an i. v. olus injection every 3 weeks. The maximum tolerated dose (MTD) was 300 mg/m2 for heavily preteated patients, while 400 mg/m2 appears to be the MTD for minimally pre-treated patients. The dose-limiting toxicity (DLT) was myelosuppression, and local irritation and phlebitis, and mild peripheral neuropathy were also observed. Phase II trials are being ini tiated in breast, colon, lung, ovarian and prostate cancer, as well as lymphomas and leukaemias [45,46]. Bryostatins Bryostatin-1 (NSC 339555) is a macrocyclic natural lactone isolated from the marine Bryozoan, Bugula neritina (Fig. 3). It has shown both antitumour as ell as immunomodulatory effects [47,48]. It is a potent activator of the protein kinase C (PKC) family, lacking tumour-promoting activity and with antagonistic effects on tumour-promoting phorbol esters. This effect is probably related to down-regulation of PKC or by specific isoform activation. It also stimulates cytokine production, bone marrow progenitor cells and neutrophils [49-51]. In vitro, bryostatin-1 has cytotoxic activity against various leukaemia and solid tumour cell lines [50]. It has also in vivo antitumour activity in various murine models, including leukemia, lymphoma, ovarian cancer and melanoma. It was shown to enhance the antitumour effects of various anticancer agents, such as vincristine, cytosine arabinoside, cisplatin, melphalan, paclitaxel and others. These effects may be schedule-dependent [47,48,52]. This agent was studied in phase I trials at different infusion schedules. The recommended doses for phase II trials were 25-35 M-g/m2 when administered over one hour for three of every four weeks; 25 u. g/m2 given as a weekly 24 hour infusion. Myalgia was the DLT in all trials. Other toxicities were joint aches and a transient decrease in platelet counts [53,54]. Notably, partial responses were reported in atients with melanoma, ovarian cancer and NHL. Phase II trials of bryostatin-1 are being conducted at various infusion regimens in a large number of tumour types in both solid and haematological malignancies. In addition, phase I trials of brystatin-1 in combination with other agents, such as cisplatin, paclitaxel, fludarabine, vincristine, cytosine arabinoside and 2-C DA are also being conducted under the sponsorship of the US NCI [51,53,54]. MGI-114 MGI-114 (6-hydroxymethylacylfulvene; HMAF; NSC 683863) is a semisynthetic derivative of illudin S, a naturally occurring sesquiterpene obtained from he mushroom Omphalotus olearius, which exerts its cytotoxic effect following its rapid intracellular uptake, covalent binding to DNA, inhibition of DNA synthesis and induction of apoptosis (Fig. 4). Binding to non-DNA cellular components appears also important for cytotoxicity [55,56]. In preclinical models, this form of DNA damage is more difficult to be repaired and requires functional DNA helicase activity. MGI-114 has shown in vitro cytotoxic activity in various human tumours and also in paediatric tumours. In vivo studies in animals bearing human tumour xenografts have shown antitumour ctivity in MX-1 breast carcinoma, MV522 lung CHjOH HO Fig. 4. Structure of MGI-114 (NSC 683863). Downloaded from annonc. oxfordjournals. org by guest on December 7, 2 010 Marine organisms and other novel natural sources of new cancer drugs 239 adenocarcinoma, DU145 and PC-3 prostate, HT-29 colon carcinoma and HL60/MRI myeloid leukaemia. It is also active in mdrl/gpl70 and other chemotherapy- resistant tumours. In preclinical models, including paediatric tumour cell lines, its antitumour effects were shown to be synergistic with paclitaxel, topotecan, irinotecan and 5-fluorouracil [55,56]. In a phase I study of MGI-114 given as a 5-minute infusion daily for 5 days every 28 days, grade 3 thrombocytopenia and neutropenia, and reversible renal damage were documented at a dose of 14 mg/m2/day. Other toxicities were nausea and vomiting, fatigue, asthenia, local phlebitis, facial flushing, alopecia and mucositis. Maximum plasma concentrations of MGI-114 in the range of levels required for in vitro cytotoxicity were obtained in the patients [57]. Therefore, the recommended dose for phase II trials was 10. 6 mg/m2/day for 5 consecutive days every 4 weeks. The US NCI is currently sponsoring rials in various solid rumours. A phase I trial widi the above mentioned schedule is also being performed in solid paediatric malignancies. Flavopiridol Havopiridol (NSC 649890) is the first cytotoxic agent in clinical trials that targets cell cycle progression at either Gl or G2 via the inhibition of cyclindependent kinases (CDKs). It is a synthetic flavone derived from the plant alkaloid r ohitukine isolated from Amoora rohituka, and later from Dysoxylum binectariferum (Fig. 5) [58]. It blocks cell growth and causes apoptosis in various rumour cell lines. It binds ATP competitively at the nucleotide-binding ite of CDKs. The G2 arrest is caused by both direct inhibition of CDK1 and changes in the regulatory phosphorylation of CDK1. The Gl arrest appears to depend on the inhibition of CDK2 and CDK4. At higher doses, flavopiridol also inhibits protein kinase A and C [58,59]. It has in vitro antiproliferative activity with IC50s between 50-200 nmol/1, and has been shown to be synergistic with various anticancer drugs, such as cisplatin, paclitaxel, 5-fluorouracil, cytosine arabinoside and topotecan. For some agents, this effect was schedule dependent (paclitaxel and 5-fluorouracil) while not for others (cisplatin). In vivo antitumour activity was demonstrated in colon, prostate, lung, breast, ovary, gastric and renal carcinomas as well as glioma, melanoma and lymphoma [58,59]. Phase I trials of flavopiridol given as a 3-day continuous i. v. infusion every 14 days have been performed [60]. The DLT was a secretory-type diarrhoea, and fatigue, asthenia, anorexia, local tumour pain, and transient rise in bilirubin was also observed. Objective responses were documented in patients with renal, gastric and colon cancer, and with NHL. The recommended dose for phase II trials was 50 mg/m2/day x 3. The initial phase II trials will e conducted in patients with colorectal, prostate, NSCLC, and renal cell carcinoma, and in patients with non-Hodgkins lymphoma and chronic lymphocytic leukaemia. Combination studies with cisplatin or paclitaxel are also being initiated in patients with advanced solid tumours. CCI-779 CCI-779 [sirolimus 42-{3-hydroxy-2-(hydroxymethyl)- 2-methylpropanoate}; NSC 683864] is a solub le structural analogue of rapamycin (sirolimus), a macrolide antibiotic isolated from Streptomyces hygroscopicus. It causes cell cycle arrest at Gl through the inhibition of signalling pathways that produce inhibition of RNA translation. It has marked immunosuppressive effects by interacting with signal transduction pathways that are critical for normal T cell function as well as for tumour cells. CCI-779 binds to immunophilins, inhibiting their function [61,62]. Being more water soluble and more stable than rapamycin, CCI-779 was selected for preclinical and potential future clinical development. It inhibits key signal transduction pathways, such as those regulated by p70s6 kinase and phosphorylated heat- and acid-stable protein (PHAS-I). The above mentioned inhibitory effect interferes with cell-cycle progression through Gl [63]. Preclinical studies suggested hat tumours with deletion of the pl5/pl6 family of CDK inhibitors, such as melanoma, may be especially susceptible to CCI-779 [62,63]. Two schedules of CCI-779 administration are being evaluated in phase I trials, weekly and daily times five every 2 weeks. Phase II trials are being planned for breast, pancreas, colon, glioma, lymphoma, small-cell lung cancer a nd melanoma [64]. Fig. 5. Structure of flavopiridol (NSC 649890). Downloaded from annonc. oxfordjournals. org by guest on December 7, 2010 240 G. Schwartsmann H3CN D-V4I J ^CH-C1 NH â⬠¢Cv .. CHa 1 LAM O CH3 Fig. 6. Structure of depsipeptide (NSC 630176). Fig. 7. Structure of rebeccamycin analog (NSC 655649). Depsipeptide Depsipeptide (NSC 630176) is a biclyclic peptide isolated from a strain of Chromobacterium violaceum by Fujisawa Pharmaceutical Co. (Fig. 6). It decreases mRNA expression of the c-myc oncogene and inhibits the growth of Hd-ras-transformed NIH3T3 clonal cell line, Ras-1. It did not affect DNA synthesis but causes cell cycle arrest at G0/G1. More recently, it was demonstrated that it acts as an inhibitor of a histone deacetylase [65,66]. It possesses potent preclinical antitumour activity both in vitro and in vivo. In vitro, depsipeptide howed cytotoxic activity in various human solid tumour cell lines, such as NSCLC, stomach, breast and colon adenocarcinomas, with IC5Os of 0. 3-3. 2 ng/ml, and was less potent against cultured normal cells. This agent appears to be also a substrate for MDR P-glycoprotein. In vivo, it showed antitumour activity against various murine and human solid tumours (such as stomach, colon, brea st and melanoma models) [65-67]. Two phase I trials of depsipeptide are being conducted using a 4 hour i. v. infusion weekly and twice-weekly, respectively, every 21 days. NSC D655649 (rebeccamycin analogue) The rebeccamycin analogue (l,ll-dichloro-6-[2-A- iethylamino]-12,13-dihydro-12-(4-0-methyl-D-glucopyranosyl)- 5H-indolo[pyrrolo[3,4-c]carbazole-5,7- (6H)-dione; NSC D655649) is a synthetic antibiotic with the antitumour properties of its less water-soluble parent compound, rebeccamycin, which was isolated from the actinomycete strain Saccharothrix aewcolingenes found in the soil in Panama (Fig. 7). It causes an unwinding of supercoiled DNA without inducing single-strand or double-strand breaks and also inhibits topoisomerase II by limiting strandpassing ability. This compound showed in vivo antitumour activity against various murine models as ell as in human tumour xenografts, such as ESC LOX melanomas and in the ESC RXK-393 renal tumour models [68]. Currently, three phase I studies of NSC D655649 in adults and one phase I trial in children are being conducted. Two adult and one paediatric trial use a single i. v. infusion every 21 days. The MTD is 572 mg/m2 and the recommended dose for phase II is 500 mg/m2 in adults. In children, the recommended dose for phase II is 585 mg/m2. The DLT was local irritation and phlebitis at the injection site, but it became nausea and vomiting, myelosuppression (mainly neutropenia) after the use of a central i. v. ine. Hyponatremia and elevations of liver enzymes were also documented (ALT/AST). Phase I trials of a 5-daily i. v. dose every 21 days revealed similar toxicity profile and produced partial responses in ovarian, gastric and cholangiocarcinoma [69]. Conclusion Nature has given a major contribution to cancer therapy. It contributed with the introduction of several active agents that dramatically changed the natural history of many types of human cancers. This new wave of natural product d erived experimental agents is offering us the opportunity to evaluate not only totally new chemical classes of anticancer agents, ut also novel and potentially relevant mechanisms of action [73-75]. Marine compounds, for instance, can interfere with very relevant intracellular targets such as signal transduction, microtubule stabilisation or new forms of interaction with DNA. They can be extremely potent in culture, with IC50S in tumour cell lines in the nanogram range [76,77]. Probably they need potency and rapid penetration in cellular membranes to protect themselves efficiently in an aquatic environment that rapidly dilute their poisons. However, these compounds can be very toxic to normal tissues as well. We are witnessing that Downloaded from annonc. xfordjournals. org by guest on December 7, 2010 Marine organisms and other novel natural sources of new cancer drugs 241 phenomenon with marine compounds that entered clinical evaluation. The same holds true for other plant- and mi crobial-derived experimental agents. Therefore, the challenge of finding more selective anticancer agents with a more favourable therapeutic index still remains. The search for new natural product derived compounds for cancer treatment will continue through an active international collaboration among researchers in investigating rainforests, coral reefs and deep subsurface thermal vents [70-72]. These efforts are being expanded by recent advances in microbial cultivation technology and nucleic acid extraction from environmental materials. A large number of novel living organisms that provide a tremendously rich reservoir of genetic and metabolic diversity are being identified. Furthermore, manipulation of microbial biosynthetic pathways making use of genetic . engineering has allowed the production of interesting molecules not generated naturally [3,72,73,78]. These unique sources of novel compounds will certainly make anticancer drug discovery even more challenging in the next years. References Famsworth NR, Akerele O, Bingel AS, et al. Medicinal plants in therapy. Bull WHO 1985; 63: 965-981. 2 Cragg GM, Newman DJ, Snader KM, et al. Natural products in drug discovery and development J Nat Prod 1997; 60: 52-60. 3 Cragg GM, Newman DJ. Discovery and development of antineoplastic agents from natural sources. Cancer Invest 1999; 17(2): 153-163. 4 Balandrin MF, Kinghorn AD, Famsw orth NR. Plant-derived natural products in drug discovery and development: An overview. In: AD Kinghorn, MF Balandrin (eds), Human Medicinal Agents from Plants. Am Chem Soc Symposium Series 534. Am Chem Soc Washington, DC, 1993, pp 2-12. Farnsworth NR. The role of ethnopharmacology in drug development. CIBA Found Symp 1994; 154: 25-41. 6 Young P. Major microbial diversity initiative recommended. ASM News 1997; 63: 417-421. 7 Samuelsson G. Drugs of Natural Origin. Swedish Pharmaceutical Press, Stockholm, 1992. 8 Christian MC, Pluda JM, Ho TC, et al. Promising new agents under development by the Division of Cancer Treatment, Diagnosis and Centers of the National Cancer Institute. Semin Oncol 1997; 24: 219-240. 9 Rosenthal J. OECD Proceedings: Investing in biological diversity. The Cairns Conference, Australia, 25-28 March, 1996. OECD Publications, Paris, 1997, pp 253. 10 Suffness M, Cragg GM, Grever MR, et al. The National Cooperative Natural Products Drug Discovery Group (NCNPDDG) and International Cooperative Biodiversity Group (ICBG) Programs. Int J Phannacogn 1995; 33 (suppl): 5-16. 11 Bergmann W, Feeney R. Contributions to the study of marine products: XXXH. The nucleosides of sponges. J Org Chem 1951; 16: 981-987. 12 Famsworth NR. The role of medicinal plants in drug development In: P Krogsgaard-Larsen, SB Christensen, H Kofod (eds), Natural Products and Drug Development Balliere, Tindall, and Cox, London, 1984, pp 8-98. 13 Cox PA. The ethnobotanical approach to drug discovery: strengths and limitations. CIBA Found Symp 1994; 185: 2 5 41. 14 Hartwell JL. Plants used against cancer. A survey. Quartennan Publications, Lawrence, 1982. 15 Han R. Recent progress in the study of anticancer drugs originating from plants and traditional medicines in China. Chin Med Sci J 1994; 9: 61-69. 16 Chabner BA. Anticancer drugs (Chapter 18). In: VT DeVita Jr, S Hellman, AS Rosenberg (eds), Cancer: Principles and Practice, 4th edn. Lippincott, Philadelphia, 1991, pp 325-417. 17 Johnson IS, Armstrong JG, Gorman M, et al. The Vinca alkaloids: a new class of oncolytic agents. Cancer Res 1963; 23: 1390-1397. 18 DeVita VT Jr. Serpick AA, Carbone PO. Combination chemotherapy in the treatment of advanced Hodgkins disease. Ann Intern Med 1970; 73: 881-895. 19 Williams SD, Birch R, Einhom LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-1440. 20 Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, J Am Chem Soc 1971; 93: 2325-2327. 21 Wall ME, Wani MC, Cook CE, et al. Plant anti-tumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 3888-3890. 22 McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage IE and IV ovarian cancer. N Engl J Med 1996; 334: -6. 23 Bertino JR. Irinotecan for colorectal cancer. Semin Oncol 1997; 24: S18-S23. 24 Pito HC, Wender DB, OConnell MJ, et al. Phase JJ trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15:2910-2919. 25 Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer. J Clin Oncol 1996; 14: 3056-3061. 26 Sikora K, Advani S, Koroltchouk V, et al. Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol 1999; 10: 385-390. 27 Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethy 1-10-(4-( 1 -piperidino)-1 -piperidino)carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944-5947. 28 DiMarco A, Gaetani M, Scarpinato B. Adriamycin (NSC 123127) a new antibiotic with antitumor activity. Cancer Chemother Rep 1969; 53: 33-37. 29 Grever MR, Chabner BA. Cancer drug discovery and development (Section 1, Chapter 18). In: VT DeVita, S Hellman, SA Rosenberg (eds), Cancer Principles and Practice of Oncology, 5th edn. Lippincott-Raven, Philadelphia, 1997, pp 328-339. 30 Powis G. Anticancer drugs: antimetabolite metabolism and natural anticancer agents. Int Encycl Pharmacol Ther 1994; 140: 1-506. 31 Jessup JM, McGinnis LS, Winchester DP, et al. Clinical Downloaded from annonc. oxfordjournals. org by guest on December 7, 2010 242 G. Schwartsmann highlights from the National Cancer Database: 1996. CA Cancer J Clin 1996; 46: 185-187. 2 Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55: 2325-2333. 33 Cragg GM, Newman DJ and Weiss RB. Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Semin Oncol 1997; 24: 156-163. 34 Kitagawa I, K obayashi M. Antitumor marine natural products. Gan To Kagaku Ryoho 190; 17(3): 322-329. 35 Kowalski RJ, Giannakakou P, Gunasekera SP, et al. The microtubule- stabilizing agent discodermolide competitively inhibits the binding of paclitaxel to tubulin polymers, enhances ubuline nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997; 52: 613-622. 36 Schmidt U, Griesser H, Hass G, et al. Synthesis and cytostatic activities of didemnin derivatives. J Peptide Res 1999; 54: 146-161. 37 Weiss RB, Peterson BL, Allen SL, et al. A phase II trial of didemnin B in myeloma. A cancer and leukemia group B (CALGB) study. Invest New Drugs 1994; 12(1): 41-43. 38 Chun HG, Davies B, Hoth D, et al. Didemnin B. The first marine compound entering clinical trials as an amineoplastic agent. Invest New Drugs 4(3): 279-284. 39 Rinehart KL. Antitumor compounds from tunicates. Med Res Ver 2000; 20(1): 1-27. 40 Takebayashi Y, Pommier Y. DNA minor groove alkylation by Ecteinascidin 743 indices sequence specific topoisomerase I-mediated DNA damage. Proc Am Assoc Cancer Res 1999; 40 (#718). 41 Pettit GR, et al. The isolation and structure of a remarkable marine animal amineoplastic constituent: Dolastatin 10. J Am Chem Sec 1987; 109: 6883-6885. 42 Bai R, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 1990; 39(12): 1941- 949. 43 Pathak S, Multani AS, Ozen M, et al. Dolastatin-10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line. Oncol Rep 1998; 5(2): 373-376. 44 Maki A, Mohammad R, Raza S, et al. Effect of dolastatin 10 on human non-Hodgkin lymphoma cell lines. Anticancer Drugs 1996; 7(3): 344-350. 45 Madden T, Tran HT, Huie R, et al. N ovel marine-derived anticancer agent: a phase I clinical, pharmacological and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 2000; 6: 1293-1301. 46 McElroy EA, Pitot HC, Erlichman C, et al. Phase I trial of dolastatin-10 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1997; abstr. #782. 47 Wender PA, Hinkle KW, Koehler MF, Lippa B. The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues. Med Res Rev 1999; 19(5): 388-407. 48 Wall NR, Mohammed RM, Nabha SM, et al. Modulation of Ciap-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in human early pre-B acute lymphoblastic leukemia cell line REH. Biochem Biophys Res Commun 1999; 266: 76-80. 49 Trenn G, Pettit GR, Takayama H, et al. Immunomodulating roperties of a novel series of protein kinase C activators. The bryostatins
Friday, March 20, 2020
U.S. President Mckinley Assassinated
U.S. President Mckinley Assassinated On September 6, 1901, anarchist Leon Czolgosz walked up to U.S. President William McKinley at the Pan-American Exposition in New York and shot McKinley at point-blank range. After the shooting, it first appeared that President McKinley was getting better; however, he soon took a turn for the worse and died on September 14 from gangrene. The daylight assassination attempt horrified millions of Americans. Greeting People at the Pan-American Exposition On September 6, 1901, U.S. President William McKinley spent the morning visiting Niagara Falls with his wife before returning to the Pan-American Exposition in Buffalo, New York in the afternoon to spend a few minutes greeting the public. By about 3:30 p.m., President McKinley stood inside the Temple of Music building at the Exposition, ready to begin shaking the hands of the public as they streamed into the building. Many had been waiting for hours outside in the heat for their chance to meet the President. Unbeknownst to the President and the many guards who stood nearby, among those waiting outside was 28-year-old anarchist Leon Czolgosz who was planning to kill President McKinley. At 4 p.m. the doors to the building were opened and the mass of people waiting outside were forced into a single line as they entered the Temple of Music building. The line of people thus came up to the President in an organized fashion, with just enough time to whisper a Nice to meet you, Mr. President, shake President McKinleys hand, and then be forced to continue along the line and out the door again. President McKinley, the 25th president of the United States, was a popular president who had just started his second term in office and the people seemed clearly glad to get a chance to meet him. However, at 4:07 p.m. Leon Czolgosz had made it into the building and it was his turn to greet the President. Two Shots Rang Out In Czolgoszs right hand, he held a .32 caliber Iver-Johnson revolver, which he had covered by wrapping a handkerchief around the gun and his hand. Although Czolgoszs swaddled hand was noticed before he reached the President, many thought it looked like it covered an injury and not that it was hiding a gun. Also, since the day had been hot, many of the visitors to see the President had been carrying handkerchiefs in their hands so that they could wipe the sweat off their faces. When Czolgosz reached the President, President McKinley reached out to shake his left hand (thinking Czolgoszs right hand was injured) while Czolgosz brought up his right hand to President McKinleys chest and then fired two shots. One of the bullets didnt enter the president - some say it bounced off of a button or off the presidents sternum and then got tucked into his clothing. The other bullet, however, entered the presidents abdomen, tearing through his stomach, pancreas, and kidney. Shocked at being shot, President McKinley began to sag as blood stained his white shirt. He then told those around him, Be careful how you tell my wife. Those in line behind Czolgosz and guards in the room all jumped on Czolgosz and started to punch him. Seeing that the mob on Czolgosz might easily and quickly kill him, President McKinley whispered either, Dont let them hurt him or Go easy on him, boys. President McKinley Undergoes Surgery President McKinley was then whisked away in an electric ambulance to the hospital at the Exposition. Unfortunately, the hospital was not properly equipped for such a surgery and the very experienced doctor usually on premises was away doing a surgery in another town. Although several doctors were found, the most experienced doctor that could be found was Dr. Matthew Mann, a gynecologist. The surgery began at 5:20 p.m. During the operation, the doctors searched for the remains of the bullet that had entered the Presidents abdomen, but were unable to locate it. Worried that continued searching would tax the Presidents body too much, the doctors decided to discontinue looking for it and to sew up what they could. The surgery was completed a little before 7 p.m. Gangrene and Death For several days, President McKinley seemed to be getting better. After the shock of the shooting, the nation was excited to hear some good news. However, what the doctors did not realize was that without drainage, an infection had built up inside the President. By September 13 it was obvious the President was dying. At 2:15 a.m. on September 14, 1901, President William McKinley died of gangrene. That afternoon, Vice President Theodore Roosevelt was sworn in as President of the United States. The Execution of Leon Czolgosz After being pummeled right after the shooting, Leon Czolgosz had been arrested and taken to police headquarters before nearly being lynched by the angry crowds that surrounded the Temple of Music. Czolgosz readily admitted that he was the one who had shot the President. In his written confession, Czolgosz stated, I killed President McKinley because I done my duty. I didnt believe one man should have so much service and another man should have none. Czolgosz was brought to trial on September 23, 1901. He was quickly found guilty and sentenced to death. On October 29, 1901, Leon Czolgosz was electrocuted.
Wednesday, March 4, 2020
The Shack Discussion Questions
'The Shack' Discussion Questions The Shack by William P. Young is a story about Mack, a man whose daughter is kidnapped and brutally murdered. A few years after her murder, Mack receives an invitation from God to meet Him at the shack where they found his daughters bloody clothes. Mack goes and works through the meaning of suffering as he spends the weekend with the Trinity. Spoiler warning: This study guide reveals important details about The Shack by William P. Young. Finish the book before reading on. Were you drawn in by the plot of The Shack?Why do you think Macks encounter with God took place at the shack? If God were to invite you somewhere, where would it be? (In other words, where is the center of your doubt and pain)?Do you think suffering makes people closer to God or causes them to distance themselves from Him? What has been the pattern in your life?Were you satisfied with Gods answers to Mack about suffering? Do you struggle with believing God is good in light of all the tragedy in the world?How is Youngs description of God different from your concept of God? What parts of his description did you like and what parts didnt you like?Did The Shack change any of your opinions about God or Christianity?What were some of the things The Shack teaches about God, faith, and life that you disagreed with?Would you recommend The Shack to a friend?Rate The Shack on a scale of 1 to 5.
Monday, February 17, 2020
The Munich Agreement of September 1938 Essay Example | Topics and Well Written Essays - 2000 words
The Munich Agreement of September 1938 - Essay Example This has made these states consider the agreement as a Munich dictate, whose aim was to allow the Germans to continue with the occupation of the Czechoslovakia land. The paper will discuss the reasons why Neville Chamberlain signed the Munich Agreement. Why Neville Chamberlain signed the Munich Agreement Neville Chamberlain was the Prime Minister of the United Kingdom at the time the Berlin agreement was signed in Munich Germany. He is seen as a conservative politician who operates under the appeasement policy. Throughout his tenure in office as British Prime Minister, he is portrayed as a leader who practiced anti-war policies and would do everything possible to ensure that peace prevail. This saw him sign the Munich Agreement despite being ridiculed and branded as a coward. This is because, Chamberlain considered the matter that was bringing disagreement between Germany and Czechoslovakia as something which could be solved diplomatically (Caputi 2000 p.187). He, therefore, sought f or a diplomatic course by trying everything possible to convince Hitler who was much opposed to the agreement to concede, sign the agreement, and avoid war ((McDonough 1998). One of the main reasons Chamberlain signed the Munich Agreement was to ensure that Britain maintained super power status in Europe, both in terms of the economy and imperial power. McDonough (1998 p.4) argues that chamberlain was an assertive politician who was realistic and able but was much aware that Britain was not in a position both military or economically to maintain control of the world. He, therefore, wanted Britain to retain its influence in Europe and retain the independence of Britain. For Britain to achieve its mission, Chamberlain felt that the best way to do this was by avoiding a world war, which was eminent (Parker 1993 P.48). He was, therefore, obliged to sign the agreement so that Britain can remain super power both economically and imperially. For a country to go into war, it needs to get su pport of the nation for it to be successful. Chamberlain signed the agreement because he was not sure as to whether he could get the support of his country in case he accepted to go into war (Grayson 2001). Before the signing of the agreement, Chamberlain kept seeking for the nation and cabinet support in his plan Z strategy in case war was unavoidable. He, however, did not get the kind of support, which made him doubt whether his nation would follow him into war. This prompted him to sign the agreement to avoid criticism from his nation (Caputi 2000 p.187). War is always associated with high costs, as it requires use of resources, arsenals and the army (Rowe 2004). Chamberlain felt that it was noble to for him to consider signing the Munich Agreement, which would prevent Britain from incurring such heavy costs associated with war. This shows that Chamberlain was not opposed to war as some historians branded him as a coward but instead he was being guided by moral values. It is only Germany that was prepared to pay these costs by ensuring that the fight for the annexation of Nazi Germans in Czechoslovakia. Chamberlain and government of France were however much opposed to subjecting their nations to these costs since the matter at hand to them was not worth the costs. This is seen in the Munich riddle that going to war need concrete cause, willingness, arsenals and the men, which to Chamberlain and Daladier were lacking according to Caputi (2000 p.192). Therefore, Chamberlain had no choice but to sign the Berlin Agreement. It is
Monday, February 3, 2020
History Assignment Example | Topics and Well Written Essays - 1500 words - 1
History - Assignment Example Gerald Ford, who became a president after Nixon resigned as the result of Watergate, granted pardon to the former president Nixon in September 1974. This action proved to be an unpopular move since Nixon was suspected to be involved in Watergate Scandal. He got another fame point reduction from the fact that his WIN (Whip Inflation Now) program failed to stop stagflation, the conditions from the era of Nixonââ¬â¢s presidency where prices and unemployment kept rising. Related to Vietnam Wars, Ford planned a renewal of U.S. military support in South Vietnam, but it failed due to the antiwar mood in the states and the battlefield conditions in Vietnam. Within the era of Fordââ¬â¢s presidency, in 1975, North Vietnamese captured South Vietnam capital Saigon, and in the same year the Khmer Rouge of Cambodia drove the U.S supported government from the capital of Phnom Penh and boarded a U.S. ship, the Mayaguez to seize the ship and its crew. Fordââ¬â¢s effort to send a rescue mission and bombing strikes led to short burst of approval from the U.S. citizens. However, during the rescue, U.S. lost more men than it saved. During Jimmy Carterââ¬â¢s era of presidency, the influence of Watergate and Vietnam Wars legacies was not as great. However, the shaken faith to the government was still suffered and the stagflation which damaged the economy condition during Nixon and Fordââ¬â¢s eras of presidencies was still unsolved. The rise of oil price and hostage crisis added more problems during Carterââ¬â¢s term in office. Related to Vietnam Wars, Carterââ¬â¢s first policy after he obtained his presidential seat was to grant amnesty to most Vietnam-era draft resisters. Declaring that he would not be afflicted by ââ¬Å"inordinate fear of communismâ⬠, Carter avoided getting involved by direct war like what happened in Vietnam Wars, and focused on diplomatic negotiations and attempts which emphasized human rights. Camp David peace talk between
Saturday, January 25, 2020
Use of Protease Inhibitors as Insecticides
Use of Protease Inhibitors as Insecticides The Plagues of Egypt are a well-known to many, to send a message to the Pharaoh, the eighth of which saw Moses have God send was a plague of locusts to destroy crops. Luckily those were mere allegorical stories. What is true is that crop yields for ancient societies have always been plagued pests destroying crops. Even in modern times pests are a major issue for farmers. Effective modern delivery methods of insecticides to fight pests such as chemical sprays like the infamous roundup by Monsanto have proven to be effective, but face issues such as potential poisons lingering in the environment, insects acquiring resistance to them over time, not being very specific in their targets often killing everything they are sprayed on, and tend to be quite toxic. A more effective method has been the use of biological pesticides, where plants in question generate toxins required to fight insects specifically without being toxic. One methods of delivery that has shown promise has been to use pr oteinase inhibitors. Proteases are found in almost all organisms playing important roles in biological processes by breaking down proteins via hydrolytic reactions (Lin et al., 2017). If proteases are overexpressed in a cell it can lead to many proteins being degraded needlessly affecting cell function (Lin et al., 2017). As a result, proteases need to be properly controlled and one of the most efficient ways to do so is with protease inhibitors. When proteinase inhibitors (PIs) bind to digestive enzymes it causes them to become unreactive (Broadway and Duffey, 1986). The pancreas would then have to secrete additional proteinases itself to fight the inhibition from inhibitors so that normal digestion can occur and prevent re-absorption of protease-inhibitor enzyme complex (Broadway and Duffey, 1986). If this process is left unhindered it would lead to loss of essential amino acids which could have be used to build more proteases (Broadway and Duffey, 1986). This loss of amino acids results in an amino ac id deficiency that leads to growth, development and survival issues of the organism (Fatemeh and Bandani, 2011). What makes proteinase inhibitors attractive for controlling pests is that they are encoded by single genes and are effective over wide ranges of pests, making them more practical than methods that rely on inhibiting complex pathways with similar targets (Fatemeh and Bandani, 2011). A substantial amount of development has gone towards finding suitable proteinase inhibitors for plants to express. Insects have also been found to be adapting against the use of protease inhibitors, with some being able to overexpress gut proteases or create new enzymes that are harder to inhibit (Nath et al., 2015). This only shows that the study of proteinase inhibitors still has a long ways to go and will require much more study. Some of the techniques studied in recent years to deter pests include use of trypsin inhibitor against lepidopteran larvae and serine proteinase inhibitors against mosquitos. It was believed that a trypsin inhibitor that was expressed in the germinating seed of Dolichos biflorus would be effective the gut proteins of P. brassicae and S. littoralis. To test this theory researchers extracted the PI from germinating various seed samples then sterilizing seeds in ethanol and water and growing them, collecting the plant seeds from flowering plants at different time intervals and then grinded them up into fine powder and processed it with acetone to get a crude extract (Nath et al., 2015). Researchers were able to measure and extract the amount of trypsin inhibitor in each seed from the crude extract via centrifugation and found that the more days after germination when they extracted the trypsin inhibitor the less the seed had (Nath et al., 2015). This decline coincided with noted decreases in soluble protein activity in the seeds after germination which could be attributed to degradation of proteins including inhibitors and proteases during germination (Nath et al., 2015). To measure trypsin inhibitor effectiveness against gut proteases of organisms, researchers also dissected the midgut of P. brassicae and S. littoralis and centrifuged it to isolate for a source of trypsin, which they found (Nath et al., 2015). To measure activity of inhibitor against gut proteases, researchers measured optical density after mixing inhibitor and gut proteases together (Nath et al., 2015). It was found in this study that all trypsin inhibitors extracted from seeds exhibited inhibitory response against P. brassicae, researchers then took the sample (HPK4) that showed highest inhibitory action and tested it against proteases of S. littoralis, and found that it also exhibited inhibitory activity making it ideal an ideal candidate for an insecticide (Nath et al., 2015). To test inhibitor ability as an insecticide researchers used cabbage leaf discs coated in trypsin inhibitor extracted from HPK4 seeds as it had the highest activity, and fed it to newly hat ched larvae for 5 days (Nath et al., 2015). The experiment measured the amount of the leaf disc eaten and fecal matter produced from larvae over the 5 day period using different concentrations of trypsin inhibitor ranging from 0.025mg to 2.5mg (Nath et al., 2015).Ãâà It was found that P. brassicae larvae were sensitive to inhibitor as they showed mortality rate ranging from 10% to 80% (at 0.025mg and 2.5mg concentration respectively) after 5 days of feeding (Nath et al., 2015). Larval fecal matter was also noted to having 38% less gut trypsin and other soluble proteins compared to fecal matter in control samples, and with less of cabbage leaf being eaten in all samples compared to control due to massive dying off of larvae (Nath et al., 2015).Ãâà Larval death could be attributed to lack of essential amino acids in insects body due to trypsin inhibitor (Nath et al., 2015). Reduced soluble protein in fecal matter was attributed to less intestinal aberration and the fact th at much less of the leaf was eaten overall (Nath et al., 2015).Ãâà Similar results were found in complementary study regarding the effects on S. littoralis, with low survival rates, reduced larval mass, and decreased soluble protein concentration in fecal matter compared to control (Nath et al., 2015). Overall researchers were able to conclude that the PIs (trypsin inhibitor in this case) from various germinating seed strains were able to inhibit gut proteinases of many lepidopteran larvae such as P. brassicae and S. littoralis (Nath et al., 2015).Ãâà It is worth noting that while this experiment used PIs as a spray over plants, researchers indicate that this holds promising future for crops to express higher levels of proteinase inhibitors naturally to fight pest populations in a way without spraying toxic pesticides (Nath et al., 2015). Another tested method to fight pests was with serine proteinase inhibitors. Mosquitoes are a major vector of disease carrying with them malaria, west nile virus, and etc, mosquitoes are found around the world and it has been reaffirmed many times that the best way to control mosquitos is through controlling populations (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013).Ãâà This topic has been studied extensively and is known that the majority of digestive enzymes for mosquitoes are serine proteases (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013). For this experiment researchers looked into Ae. aegypti a mosquito strain which is found commonly around the world (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013). It was determined that mosquito larvae would be the ideal target for this protease inhibitors because they are aquatic and feed constantly which would give inhibitors the greatest chance to succeed in killing them as they are in early development (Soares, Soar es Torquato, Alves Lemos, Tanaka, 2013). To determine which serine proteases were present in mosquito larvae researchers performed a kinetic assay of larval midgut proteins and determined that the gut extract was a host to trypsin-like, elastase-like, and chymotrypsin-like enzymatic activities (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013). Researchers then used a phage display system to select an inhibitor for all of these digestive proteases, finding that HiTI a trypsin inhibitor from the horn fly would suffice because of successful detection for HiTI on an active M13 phage as it was fused to coat one of the coat proteins (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013).Ãâà Researchers then created aÃâà combinatorial HiTI inhibitor library and tested for their ability to inhibit the serine proteases in mosquito larvae and their ability to inhibit the trypsin-like, chymotrypsin-like and elastase-like proteases (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013). Amino acid analysis of phagemid DNA indicated that for HiTI, the largest area for variation occurred in the P1 position of the enzyme (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013). This was important because it appeared this position determined the specificity of the HiTI inhibitor, as it was found that if a basic amino acid was present in P1 it would inhibit trypsin, while chymotrypsin would be inhibited if hydrophobic amino acids was present, and if small aliphatic amino acids are present then elastase would be inhibited (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013). Among the library created mutants that would inhibit one of the three noted above were found with majority of clones not being proteases (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013). Researchers then proceeded to purify and clone the HiTI variants into a plamids which experessed in P.pastoris (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013).It was found that the wild type HiTI was able to inhibit the trypsin-like enzymes but not the remaining two (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013). Researchers were able to find 3 mutants that inhibited trypsin-like enzymes but did not inhibit elastase-like and chymotrypsin-like enzymatic reactions, two variants were found to inhibit chymotrypsin with high selectivity for bovine chymotrypsin, one of which (T23) was also found to be an inhibitor for elastase-like proteases as well reaffirming the researchers belief in specific selection by inhibitors for different proteases (Soares, Soares Torquato, Alves Lemos, Tanaka, 2013). The results of this research are promising because this study provides a better understanding of mosquito gut enzymes and provides a framework for insecticide development based on protease inhibitors for mosquitos. In conclusion, it was found that proteinase inhibitors are a viable methods for controlling pests whether it is controlling mosquito populations by feeding larvae serine proteinase inhibitor or coating crops with trypsin inhibitors and feeding it to pests. Much of the work currently has been formed around determining which proteinase inhibitors would match well with their intended target. In order to expand the scope and make proteinases a functional insecticide it would seem more work needs to be done around delivery systems, whether it be as a chemical insecticide spray or genetically altering plants to overexpress proteinase inhibitors. Over time as this field becomes more developed we can be able to determine the effects of these inhibitors on humans. The concept has been proven and more work is needed to make them viable, proteinase inhibitors have a strong future and once the kinks have been worked out then there is no doubt they will be massively successful in increasing crop yields and fighting off pests. References Dantzger, M., Vasconcelos, I. M., Scorsato, V., Aparicio, R., Marangoni, S., Macedo, M. L. R. (2013). Bowman-Birk proteinase inhibitor from Clitoria fairchildiana seeds: Isolation, biochemical properties and insecticidal potential. Phytochemistry, 118(August), 224-235. http://doi.org/10.1016/j.phytochem.2015.08.013 Lin, H., Lin, X., Zhu, J., Yu, X.-Q., Xia, X., Yao, F., You, M. (2017). Characterization and expression profiling of serine protease inhibitors in the diamondback moth, Plutella xylostella (Lepidoptera: Plutellidae). BMC Genomics, 18(1), 162. http://doi.org/10.1186/s12864-017-3583-z Nath, A. K., Kumari, R., Sharma, S., Sharma, H. (2015). Biological activity of Dolichos biflorus L. trypsin inhibitor against lepidopteran insect pests. Indian Journal of Experimental Biology, 53(September), 594-599. Soares, T. S., Soares Torquato, R. J., Alves Lemos, F. J., Tanaka, A. S. (2013). Selective inhibitors of digestive enzymes from Aedes aegypti larvae identified by phage display. Insect Biochemistry and Molecular Biology, 43(1), 9-16. http://doi.org/10.1016/j.ibmb.2012.10.007 Broadway, R. M., Duffey, S. S. (1986). Plant proteinase inhibitors: Mechanism of action and effect on the growth and digestive physiology of larval Heliothis zea and Spodoptera exigua. Journal of Insect Physiology, 32(10), 827-833. http://doi.org/10.1016/0022-1910(86)90097-1 Saadati, F., Bandani, A. R. (2011). Effects of Serine Protease Inhibitors on Growth and Development and Digestive Serine Proteinases of the Sunn Pest, Eurygaster integriceps. Journal of Insect Science (Online), 11(72), 72. http://doi.org/10.1673/031.011.7201
Subscribe to:
Posts (Atom)